Transdermal buprenorphine in clinical practice - A post-marketing surveillance study in 13179 patients

Current Medical Research and Opinion

Volumn 21, Issue 8, 2005, Pages 1147-1156

  Griessinger, Norbert ^a   Sittl, Reinhard ^a   Likar, Rudolf ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b GENERAL HOSPITAL KLAGENFURT   (Austria)

Author keywords

Buprenorphine; Chronic pain; Non interventional study; Observational studies; Opioids

Indexed keywords

BUPRENORPHINE; CYCLOOXYGENASE 2 INHIBITOR; DIHYDROCODEINE; FENTANYL; HYDROMORPHONE; MORPHINE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; PETHIDINE; TILIDINE; TRAMADOL;

ADOLESCENT; ADULT; AGED; ALLERGIC REACTION; ANALGESIA; ARTICLE; CANCER PAIN; CLINICAL PRACTICE; CONFUSION; CONSTIPATION; CONTACT DERMATITIS; CONTROLLED STUDY; DERMATITIS; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG EFFICACY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DYSPNEA; ERYTHEMA; FATIGUE; FEMALE; GERMANY; HEADACHE; HUMAN; HYPERHIDROSIS; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROPATHY; PAIN; PAIN ASSESSMENT; POSTMARKETING SURVEILLANCE; PRURITUS; PSYCHOSIS; RASH; SKIN IRRITATION; SLEEP DISORDER; TRANSDERMAL PATCH; URINE RETENTION; VOMITING; XEROSTOMIA;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; BUPRENORPHINE; CHRONIC DISEASE; FEMALE; HEALTH CARE SURVEYS; HUMANS; MALE; MIDDLE AGED; OBSERVATION; PAIN; PRODUCT SURVEILLANCE, POSTMARKETING; TREATMENT OUTCOME;

EID: 23744461066     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X53315     Document Type: Article

References (21)

1. WHO: Cancer pain relief. With a guide to opioid availability. Geneva 1996
2. Caplan RA, Southam M. Transdermal drug delivery and its application to pain control. Adv Pain Res Ther 1990;14:233-40
3. Grond S, Radbruch L, Lehmann KA. Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl. Clin Pharmacokinet 2000;38:59-89
4. Payne R. Experience with transdermal fentanyl in advanced cancer pain. Eur J Pain 1990;11:98-101
5. Zech D, Grond S, Lynch J. Subcutaneous and transdermal administration of opioids in cancer pain. Eur J Pain 1993;14:69-78
6. Picard PR, Tramer MR, McQuay HJ, Moore RA. Analgesic efficacy of peripheral opioids (all except intra-articular): a qualitative systematic review of randomised controlled trials. Pain 1997;72:309-18
7. Finco G, Polati E, Bartoloni A, Milan B, Zanoni L, Valle L. Intravenous patient-controlled analgesia (PCA) in the treatment of postoperative pain: rationale and clinical application. Chir Ital 1995;74:20-5
8. Heel RC, Brodgen RN, Speight TM, Avery GS. Burprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs 1979;17:81-119
9. Budd K. High dose buprenorphine for postoperative analgesia. Anaesthesia 1981;36:900-3
10. Benedetti F, Vighetti S, Amanzio M, et al. Dose-response relationship of opioids in nociceptive and neuropathic postoperative pain. Pain 1998;74:205-11
11. Budd K. Buprenorphine and the transdermal system - the ideal match in pain management. Int J Clin Pract Suppl 2003;133:9-14
12. Böhme K, Likar R. Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS), in the treatment of patients with chronic pain. A randomized, double-blind, placebo-controlled study. The Pain Clinic 2003;15:193-202
13. Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: A multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 2003;25:150-168
14. Sorge J, Sittl R. Transdermal buprenorphine in chronic pain: results from a phase III, randomized, double-blind, placebo-controlled multicenter study. Clin Ther 2004;26:1808-20
15. Transtec. Summary of product characteristics. 2001
16. Nossol S, Schwarzbold M, Stadler T. Treatment of pain with sustained-release tramadol 100, 150, 200 mg: results of a post-marketing surveillance study. Int J Clin Pract 1998;52:115-21
17. Radbruch L, Sabatowski R, Petzke F, Brunsch-Radbruch A, Grond S, Lehmann KA. Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients. Palliative Med 2001;15:309-21
18. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. New Engl J Med 2000;342:1878-86
19. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. New Engl J Med 2000;342:1887-92
20. Pocock SJ, Elbourne DR. Randomized trials or observational tribulations? New Engl J Med 2000;342:1907-9
21. Janssen-Cilag. SmPC Durogesic SMAT. Section 4.1. 2004